Introduction: BAY 94-9027 is an extended-half-life, site-specifically PEGylated, Bdomain-deleted recombinant factor VIII (FVIII). The PROTECT VIII main study demonstrated efficacy of bleed control using extended-interval prophylaxis with BAY 94-9027 for 36 weeks. Aim: To report long-term efficacy and safety of prophylaxis with BAY 94-9027 in a descriptive analysis of the ongoing PROTECT VIII extension with a total treatment time of up to >5 years. Methods: Previously treated males aged 12-65 years with severe haemophilia A who completed the PROTECT VIII main study were eligible for the open-label extension.
| MATERIAL S AND ME THODS

| Patients and study design
Patients aged 12-65 years who completed the PROTECT VIII main study 19 were eligible for inclusion in the multicentre, open-label, uncontrolled, ongoing PROTECT VIII extension. The extension study took place across 52 treatment centres from 18 countries; it began in February 2013 on a rolling basis, (hereby referred to as extension enrolment) as each patient completed the main study. Patients treated on demand during PROTECT VIII had the option to either continue on-demand treatment in the extension or switch to 1 of 3 prophylaxis groups (30-40 IU/kg twice weekly, 45-60 IU/kg every 5 days or 60 IU/kg every 7 days). Patients who received prophylaxis in the main study could either continue their regimen or switch regimens at the beginning or at any time during the extension; treatment adjustments were based on the clinical bleeding pattern, and as such, trough levels were not determined for the purposes of such treatment decisions. All patients who switched regimens at least once after the first week of the extension were analysed in a separate variable frequency group.
The dose and number of infusions of BAY 94-9027 needed to treat breakthrough bleeding were determined at physician discretion up to a maximum recommended dose of 60 IU/kg/infusion or 6000 IU/ infusion. All patients provided written informed consent, and the protocol was approved by each site's independent ethics committee and/ or institutional review board. Results are reported from an analysis of data collected by 31 January 2018 after up to >5 years in the study.
| Efficacy and safety assessments
Efficacy of BAY 94-9027 was assessed using electronic patient diaries (EPDs) to document number and dose of infusions, adherence with prophylaxis regimen, reasons for treatment, bleeding events, bleed characteristics and response to treatment of bleeds (subject or investigator assessment as excellent, good, moderate, poor).
Annualized bleeding rates (ABRs) were calculated for each dosing group and for the variable frequency group. In a separate analysis, ABRs and other bleeding outcomes were calculated for the last 12 months of the extension in patients who had participated in the extension for ≥12 months by the January 2018 interim analysis period. Throughout the extension study, patients were closely monitored at visits every 6 months for the incidence of adverse events (AEs), including inhibitor development, which were documented in terms of type, severity and relationship to study drug. Inhibitor development was defined as a Nijmegen-modified Bethesda assay measured titre of ≥0.6 BU that was confirmed in a second independent sample (ideally collected within 2 weeks of the first inhibitor detection).
| Statistical analysis
ABRs were calculated for each dosing group (twice-weekly, every-5days, and, every-7-days-patients who did not change regimen after the first week of the extension) as well as for the variable frequency group. The safety population comprised all participants in the extension study who received ≥1 dose of BAY 94-9027. Efficacy variables were evaluated in the intent-to-treat (ITT) population for the extension period, which included patients in the safety population with available information regarding bleeds. Summary statistics and Abbreviation: BMI, body mass index.
TA B L E 1 Demographics of patients in the PROTECT VIII extension study
*Patients who switched regimens during the extension (switched to a higher frequency, n = 20; switched to a lower frequency, n = 4; switched twice and finished with their original frequency, n = 4).
frequencies were calculated using SAS ® version 9.2 (SAS Institute Inc) for continuous data and categorical data, respectively. Censoring was not used.
| RE SULTS
| Patients
Of 134 patients who were treated in the PROTECT VIII main study, 
| Treatment exposure
| Efficacy
The median ABR (Q1; Q3) for total bleeds was 1.6 (0.3; 4.6) and 34.1 (Figure 4 ).
| Safety
During the extension, 9 patients (7.4%; all receiving prophylaxis) expe- Both ABR for total bleeds and the percentage of patients who experienced ≥1 bleed were further reduced in the total prophylaxis group during the last 12 months of the extension, which may suggest that bleeding outcomes improved as regimens were adjusted to accommodate the individual needs of patients. This bleeding reduction may also reflect improvement in synovitis with fewer bleeds over time. Consistent with this, during the last 12 months of the extension, patients who remained in the every-7-days treatment arm had a median ABR of 0 with 64.7% of patients remaining bleed-free. ABRs for all prophylaxis groups were also further reduced in the extension compared with results of the PROTECT VIII main study. 19 No patients developed FVIII inhibitors, and the majority of AEs were mild or moderate in severity, indicating that BAY 94-9027 was well tolerated. While the resolution of bleeds ( Figure 4 ) showed that patients on prophylaxis who had bleeding episodes reported more "moderate" results which do not appear as favourable as the on-demand treatment, which may be explained by "milder" bleeds on prophylaxis and less prominent relief after treatment with FVIII. Patients in the variable frequency group had a median ABR of 3.1, but were able to switch regimens as necessary to manage bleeds F I G U R E 2 ABR by treatment regimen in the PROTECT VIII extension and negative binomial model. ABR = annualized bleeding rate; CI = confidence interval; Q, quartile; RR = rate ratio; *Patients who switched regimens during the extension (switched to a higher frequency, n = 20; switched to a lower frequency, n = 4; switched twice and were receiving their original frequency at interim analysis, n = 4 Cambridge, MA), median ABR for total bleeds was 1.6. 22 In a clinical trial evaluating efficacy of antihaemophilic factor (recombinant), PEGylated (Adynovate ® ; Baxalta, Westlake Village, CA), median ABR for total bleeds was 1.9 among 120 patients aged ≥12 years receiving prophylaxis twice weekly. 23 Results were similar in the current study, in which patients receiving up to every-7days prophylaxis with BAY 94-9027 had a median ABR for total bleeds of 1.6. Nevertheless, the mean interval between infusions was 5.2 days with BAY 94-9027, as compared with 3.5 days for the other products. 
| D ISCUSS I ON
